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Abstract
Purpose Overlooking other medical conditions during cancer treatment and follow-up could result in excess morbidity and
mortality, thereby undermining gains associated with early detection and improved treatment of cancer. We compared the quality
of care for diabetes patients subsequently diagnosed with breast, colorectal, or prostate cancer to matched, diabetic non-cancer
controls.
Methods Longitudinal cohort study using primary care records from the Clinical Practice Research Datalink, United Kingdom.
Patients with pre-existing diabetes were followed for up to 5 years after cancer diagnosis, or after an assigned index date (non-
cancer controls). Quality of diabetes care was estimated based on Quality and Outcomes Framework indicators. Mixed effects
logistic regression analyses were used to compare the unadjusted and adjusted odds of meeting quality measures between cancer
patients and controls, overall and stratified by type of cancer.
Results 3382 cancer patients and 11,135 controls contributed 44,507 person-years of follow-up. In adjusted analyses, cancer
patients were less likely tomeet five of 14 quality measures, including: total cholesterol ≤ 5mmol/L (odds ratio [OR] = 0.82; 95%
confidence interval [CI], 0.75–0.90); glycosylated hemoglobin ≤ 59 mmol/mol (adjusted OR = 0.77; 95% CI, 0.70–0.85); and
albumin creatinine ratio testing (adjusted OR = 0.83; 95% CI, 0.75–0.91). However, cancer patients were as likely as their
matched controls to meet quality measures for other diabetes services, including retinal screening, foot examination, and dietary
review.
Conclusions Although in the short-term, cancer patients were less likely to achieve target thresholds for cholesterol and HbA1c,
they continued to receive high-quality diabetes primary care throughout 5 years post diagnosis.
Implications for Cancer Survivors These findings are important for cancer survivors with pre-existing diabetes because they
indicate that high-quality diabetes care is maintained throughout the continuum of cancer diagnosis, treatment, and follow-up.
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Introduction
Early detection and advances in therapy and supportive care
have substantially improved the relative survival of many of
the most common types of cancer [1]. Consequently, overall
morbidity and mortality in cancer depend increasingly on the
quality and outcomes of primary care for underlying condi-
tions [2]. In response, Cancer Research UK (CRUK) and other
cancer organizations, such as Macmillan Cancer Support,
have expressed concern that overlooking other medical con-
ditions during cancer treatment and follow-up could result in
excess morbidity and mortality. This, in turn, could undermine
gains associated with early detection and improved treatment
of cancer [3, 4].
Although cancer could have an adverse impact on many
underlying conditions, and vice-versa, the quality and out-
comes of diabetes care in cancer deserve specific attention
for the following reasons. First, diabetes and cancer are com-
mon, especially in older people. Second, diabetes and some
types of cancer, including breast and colorectal, co-occur at
rates that are higher than expected by chance alone. This im-
plies shared risk factors and, possibly, causal mechanisms [5].
Third, some types of cancer treatments, for instance, androgen
deprivation therapy for prostate cancer [6], appear to increase
the risk of diabetes and related complications. Fourth, diabetes
is associated with excess morbidity andmortality in cancer [7].
There have been several of studies on the quality of diabe-
tes care in cancer patients, predominantly in the United States
(US) [8–14]. However, these studies have produced inconsis-
tent findings on the impact of cancer on the provision of med-
ical services, laboratory testing, and control of blood pressure,
cholesterol, and glycosylated hemoglobin (HbA1c). While
patients in the US and United Kingdom (UK) may be clini-
cally similar in many respects, differences in the organization,
delivery, and financing of primary care services between the
two countries, including historically poorer coverage of pre-
ventative services by public health insurers in the US, could
undermine the generalizability of US studies to the UK.
In the UK, evidence is limited to one study based on the UK
General Practice Research Database (2003–2006). In this study,
long-term survivors of breast, colorectal, or prostate cancer
were followed for blood pressure, cholesterol, andHbA1cmon-
itoring and control beginning at least 5 years after cancer was
diagnosed [15]. However, the study was conducted in long-
term survivors, and did not assess differences in the quality of
diabetes primary care during the first 5 years after cancer. This
was a limitation acknowledged by the investigators, who called
for research on the shorter-term consequences of cancer [15].
Also, the study did not include an assessment of other diabetes
primary care services, such as retinal screening and foot exam-
ination. Furthermore, it was conducted when the Quality and
Outcomes Framework (QOF)—the annual reward and incen-
tive program detailing practice achievement results, which
rewards practices for the provision of quality care and helps
standardize improvement in the delivery of primary medical
services—was first implemented.
The aim of this study was to compare the quality of diabe-
tes primary care between diabetic patients subsequently diag-
nosed with breast, colorectal, or prostate cancer and matched,
diabetic, non-cancer controls during the first 5 years after can-
cer diagnosis.
Method
Study design and data source
This was a longitudinal cohort study using primary care re-
cords from the UK Clinical Practice Research Datalink
(CPRD) [16]. The CPRD contains information on demo-
graphics, symptoms, tests, diagnoses, therapies, health-
related behavior, and referrals to secondary care for over
11.3 million patients from 674 general practitioner (GP) prac-
tices in the UK [17]. There are 4.4 million active (alive, cur-
rently registered) patients in the database, which is approxi-
mately 6.9% of the UK population. These patients are broadly
representative of the UK general population in terms of age,
sex, and ethnicity.
Patient selection
Selection of cancer patients
Diabetic cancer patients were included if they met all of the
following criteria: (A) diagnosed with breast, colorectal, or
prostate cancer on or after January 1, 2000; (B) diagnosed
with diabetes at least 2 years before their date of cancer
diagnosis (index date); (C) had no other cancer diagnosis,
except non-melanoma skin cancer, before their index date;
(D) were age ≥ 50 years at their index date; (E) had at least
2 years of eligible CPRD data before their index date,
where Beligible CPRD data^ was defined as the later of
their GP practice up-to-standard date or their practice reg-
istration date; (F) had an index date before the end of the
eligible CPRD data, where Bend of the eligible CPRD data^
was defined as the earliest of death, transfer out of the GP
practice, or the date of their practice’s last data upload; and
(G) survived at least 1 year after cancer diagnosis. Men
with breast cancer were excluded. Read codes from the
Department of Health, Data and Business (QOF) Rules,
Cancer and Diabetes Indicator Sets, version 25.0 [18], were
used to identify diabetes and cancer in CPRD. Read codes
are a standard terminology for describing the care and treat-
ment of patients in UK primary care.
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Selection of controls
Each diabetic cancer patient was matched to up to four dia-
betic, non-cancer controls on GP practice number, sex, and
age (± 1 year) at cancer diagnosis. Matched controls were
assigned an index date within 1 year of their cancer case,
and also required to have met inclusion criteria B–G above.
In addition to three separate cancer/control cohorts, cancer
patients and controls were combined into a single cohort
(Bcombined cancer cohort^).
Propensity score matching
For purposes of conducting sensitivity analyses, propensity-
matched cohorts also were constructed from those cohorts
described above. In this study, the propensity score was the
conditional probability of being diagnosed with one of the
three types of cancers that defined entry into the cohorts for
the cancer cases. First, binary logistic regression using back-
wards stepwise elimination of predictors [19, 20] with a prob-
ability (P) value > 0.2 was used to estimate the conditional
probability of Bassignment^ to cancer or control given the
following vector of demographic and clinical covariates: de-
mographic characteristics consisting of age at index date, sex,
calendar year of index date, most recent smoking status, most
recent drinking status, and Index of Multiple Deprivation
(IMD) quintile, from least deprived = 1 to most deprived = 5;
clinical characteristics consisting of body mass index (BMI),
Charlson Comorbidity Index, history of other cardiovascular
disease (atrial fibrillation, coronary heart disease, heart failure,
hypertension, and stroke/transient ischemic attack), history of
microvascular complications of diabetes (retinopathy, neurop-
athy, nephropathy, and chronic kidney disease), history of
macrovascular complications of diabetes (peripheral arterial
disease, acute myocardial infarction, cerebrovascular acci-
dent, and lower limb amputation), and history of anti-
diabetic medications; and laboratory characteristics consisting
of blood pressure (mm Hg), total cholesterol (mmol/L), and
HBA1c (mmol/mol). Second, the predicted conditional prob-
abilities of cancer from the final models were transformed into
logits (ln[p/1−p]) to normalize their distributions [21]. Third,
nearest neighbor matching within a caliper of 0.25σ was used
to match controls 1:1 to cancer cases.
Follow-up
Patients were followed from 2 years before, up to 5 years after,
their index date. They were censored at the earliest of the
following: the end of the year of follow-up preceding the
one in which they died, e.g., a patient who died during the
third year after their index date was censored at the end of the
second year of follow-up; the end of the year of follow-up
preceding the one containing their last date of eligible data;
or 5 years after their index date.
Variables
Primary outcome measures
Measures used to compare the quality of diabetes primary care
between cancer patients and controls were based on the QOF
diabetes indicator set (Box) [18].
Box: primary outcome measures
• Last blood pressure reading in the year was ≤ 150/90 mmHg. (QOF
DM002)
• Last blood pressure reading in the year was ≤ 140/80 mmHg. (QOF
DM003)
• Last total cholesterol test result in the year was ≤ 5 mmol/L. (QOF
DM004)
•Received an albumin creatinine ratio test during the year. (QOFDM005)
• Treated with an ACE-I or an ARB during the year (applies only to those
diagnosed with nephropathy or microalbuminuria). (QOF DM006)
• Last HbA1c test in the year was ≤ 59 mmol/mol. (QOF DM007)
• Last HbA1c test in the year was ≤ 64 mmol/mol. (QOF DM008)
• Last HbA1c test in the year was ≤ 75 mmol/mol. (QOF DM009)
• Influenza immunization during the year. (QOF DM010)
• Retinal screening during the year. (QOF DM011)
• Foot examination during the year. (QOF DM012)
• Dietary review during the year. (QOF DM013)
• Male patient asked about erectile dysfunction during the year. (QOF
DM015)
• Male patient received advice/assessment of erectile dysfunction during
the year. (QOF DM016)
Since all QOF indicators are based on annual assessments,
only patients alive at the end of the year were included in the
Bat risk^ population for that year; therefore, patients who sur-
vived less than 1 year after their index date were excluded.
In order to construct clinical/test-based quality measures
(blood pressure, cholesterol, and HbA1c), results of tests and
blood pressure readings were obtained from 2 years before the
index date until the end of the last full year (up to five) the
patient remained in the study. Patients were considered to have
met the quality measure in a specific year if their last reading
or test result in that year was at or below the threshold spec-
ified in the corresponding QOF indicator. Patients who had no
results during a specific year were considered not to have met
the measure during that year. Read codes from the diabetes
QOF Indicator Set [18] were used to construct quality mea-
sures based on the delivery of diabetes primary care services.
Patients with no record of a specific service during a specific
year were considered not to have met the quality measure in
that year.
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Covariates
Baseline demographic characteristics consisted of age at index
date, sex, calendar year of index date, most recent smoking
status, most recent drinking status, and IMD quintile. Baseline
clinical characteristics included BMI, Charlson Comorbidity
Index [22, 23], and history of microvascular and
macrovascular complications of diabetes. Complications were
identified using Read Codes [24] present in patient records at
any time prior to the index date.
Baseline laboratory values consisted of blood pressure, total
cholesterol, and HbA1c. These were identified using the most
recent result within 1 year prior to the index date. Categorical
variables for laboratory values were constructed using the dia-
betes QOF rules: blood pressure ≤ 140/80 mmHg, total choles-
terol ≤ 5 mmol/L (193 mg/dL), and HbA1c ≤ 59 (7.5%), 59 to
≤ 64 (8.0%), 64 to ≤ 75 (9.0%), and > 75 mmol/mol. Baseline
medications included antidiabetic agents, lipid lowering agents,
and medications for blood pressure. Baseline medications were
identified using British National Formulary (BNF) codes in the
CPRD Therapy file [25] within 1 year prior to the index date.
Several approaches to addressing potential problems
caused by missing data, including multiple imputations [26],
were considered for this study. However, absence of data on
important baseline variables such as smoking status, BMI, and
HbA1c could have been informative, i.e., indicators of poor
quality of care or lower GP contact prior to the index date.
Therefore, where applicable, separate categories for missing
data were constructed for baseline demographic, clinical, and
treatment variables.
Statistical methods
Multilevel logistic regression analyses were performed to es-
timate the unadjusted and adjusted odds ofmeeting each of the
quality measures in cancer patients compared to controls. All
covariates described in the section above (and included in the
propensity score matching) were included in the adjusted anal-
yses. In addition, test result-based quality measures were
partitioned into the probability of being measured/tested, and
the conditional (upon being measured/tested) probability of
meeting the measure/test threshold.
Primary analyses
The primary analyses were conducted using up to 5 years of
follow-up after the index date. Unadjusted analyses included
cancer (yes/no) and time (in years) as independent variables.
Adjusted analyses also included all baseline demographic and
clinical characteristics (described in the previous section), as
well as time, as independent variables. Furthermore, in order
to examine whether the effect of cancer on outcomes changed
over time, we performed an additional adjusted analysis for
each outcome measure in which we also included an interac-
tion term for cancer and time. We then compared the two
models (with versus without the interaction term) for each
outcome measure using the likelihood ratio test to determine
whether adding the interaction term improved the fit of the
model.We interpreted a statistically significant (p ≤ 0.05) like-
lihood ratio test as indicating that the effect of cancer on the
outcome measure changed significantly over time.
Given the large number of multivariate analyses, adjust-
ment for multiple comparisons was performed using the
Benjamini-Hochberg [27–29] approach. P values from a fam-
ily of comparisons (defined as the set of multivariate analyses
performed on one cohort) were ordered from high to low and
then compared to the corresponding Benjamini-Hochberg
threshold for statistical significance.
Secondary analyses
Secondary analyses consisted of repeating the adjusted prima-
ry analyses using all 7 years of data including 2 years prior to
the index date, and of repeating both the adjusted primary and
secondary analyses using the propensity matched cohorts.
Multilevel logistic regression analyses were performed in
STATA 14 [30] using the xtset and xtlogit commands [31].
Results
There were 14,517 patients in combined cohort: 3382 (23.3%)
cancer patients and 11,135 (76.7%) controls (see Appendix A
for characteristics). Overall, the median length of follow-up
was 1274 days (3.5 years), and follow-up was statistically
significantly shorter in cancer patients (median 1187 days)
than controls (median 1295 days: log-rank test for equality
of survivor functions p < 0.0001).
Unadjusted plots of the annual proportions of patients
meeting the quality measures suggest that, compared to non-
cancer controls, (A) slightly lower proportions of prostate
cancer patients achieved cholesterol control (total cholesterol
≤5 mmol/L), (B) lower proportions of breast and colorectal
cancer patients achieved HbA1c control (HbA1c ≤ 59 mmol/
mol), and (C) lower proportions of breast and colorectal can-
cer patients received an albumin creatinine ratio test—at least
during the first year after cancer diagnosis (Fig. 1). In contrast,
higher proportions of prostate cancer patients received influ-
enza immunization (Fig. 2). There were no discernable differ-
ences between the proportions of cancer patients and controls
meeting other quality measures for retinal screening, foot ex-
amination, dietary review (Fig. 2), ACE-I or ARB use for
nephropathy/micro-albuminuria, or those for erectile dysfunc-
tion (presented in Appendix B, since they applied only to
select subsets of the study population).
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Primary analyses
The results of the primary multilevel logistic regression anal-
yses (Table 1) show that in the combined cohort, after adjust-
ment for baseline characteristics and for multiple compari-
sons, cancer patients were statistically significantly (p ≤
0.05) less likely than non-cancer controls to meet five of 14
quality measures examined, including: total cholesterol
≤5 mmol/L (adjusted OR = 0.82; 95% CI, 0.75–0.90);
HbA1c ≤ 59 mmol/mol (adjusted OR = 0.77; 95% CI, 0.70–
0.85); and albumin creatinine ratio testing (adjusted OR =
0.83; 95% CI, 0.75–0.91). Cancer patients were statistically
significantly more likely than non-cancer controls to receive
influenza immunization (adjusted OR = 1.31; 95% CI, 1.07–
1.59), and to get advice about erectile dysfunction. Cancer
patients were as likely as their matched controls to meet qual-
ity measures for other diabetes services, including retinal
screening, foot examination, and dietary review.
Of note, adjusted odds ratios for the three HbA1c indica-
tors, as well as those for the two blood pressure indicators,
were similar (Table 1). This indicates that it is unlikely cancer
patients had slightly higher thresholds than the controls, which
were missed simply because the binary measures were not
sufficiently sensitive to detect small differences between the
two groups. Also, there were few instances in which adding an
interaction for cancer and time significantly improved the
goodness of fit of the adjusted model (Table 1), indicating that
the impact of cancer on the outcome measures did not change
over time.
In some instances, the impact of cancer on the quality of
diabetes primary care differed across the three individual can-
cer cohorts. For example, in the breast cancer cohort, the ad-
justed OR for total cholesterol ≤ 5 mmol/L was 1.03 (95% CI,
0.88–1.21), but in prostate cancer it was 0.66 (95% CI, 0.57–
0.76). In the breast cancer cohort, the adjusted OR for influ-
enza immunization was 0.95 (95% CI, 0.68–1.34), but in
Fig. 1 Unadjusted proportions of patients meeting quality measures
based on testing. Unadjusted proportions (dots) and 95% confidence
intervals (bars) of cancer patients (red) and controls (blue) meeting
select quality measures based on testing (Fig. 1) and services (Fig. 2),
from 2 years before, up to 5 years after, the date of cancer diagnosis or
matched date in the control group (index date). Plots for other quality
measures not shown here (blood pressure ≤ 150/90 mmHg, diagnosis of
nephropathy or micro-albuminuria who were treated with an angiotensin
converting enzyme inhibitor or angiotensin receptor blocker, HbA1c ≤
64 mmol/mol, HbA1c ≤ 75 mmol/mol, asked about erectile dysfunction,
received advice about erectile dysfunction) are provided in Appendix B
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prostate cancer it was 2.18 (95% CI, 1.56–3.06). In other
instances, findings were consistent across the cohorts.
Findings from the analyses in which the test-based quality
measures were partitioned into (A) being tested (yes/no) in
that year, and (B) meeting the test result threshold for that
quality measure (yes/no) conditional upon having been tested
are reported in Appendix C. The results indicate that overall
differences between cancer patients and controls were due to a
combination of differences in testing and meeting the test
thresholds; however, this varied by type of cancer.
Secondary analyses
Comparison of demographic and clinical characteristics, as well
as laboratory values and medications, showed substantial im-
provement in the balance of individual characteristics between
cancer patients and controls after propensity score matching.
After matching, there were no statistically significant differences
in the distributions of any categorical variables. However, small
differences between cancer patients and controls also remained
in mean diastolic blood pressure (0.52 mmHg higher in cancer)
and in total cholesterol (0.03 mmol/L higher in cancer). Finally,
a comparison of mean logit scores (propensity scores trans-
formed by ln [P/1-P] to normalize the distributions) between
cancer patients and controls confirmed no statistically significant
difference after matching (p = 0.51).
Findings from the multivariate analyses based on the propen-
sitymatched cohorts, and those that included 2 years of data prior
to cancer diagnosis or the matched index date for controls, were
consistent with those from the primary analyses. (Appendix D).
Discussion
Leading cancer organizations in the UK have expressed con-
cern that overlooking other conditions during cancer treatment
Fig. 2 Unadjusted proportions of patients meeting quality measures
based on services. Unadjusted proportions (dots) and 95% confidence
intervals (bars) of cancer patients (red) and controls (blue) meeting
select quality measures based on testing (Fig. 1) and services (Fig. 2),
from 2 years before, up to 5 years after, the date of cancer diagnosis or
matched date in the control group (index date). Plots for other quality
measures not shown here (blood pressure ≤ 150/90 mmHg, diagnosis of
nephropathy or micro-albuminuria who were treated with an angiotensin
converting enzyme inhibitor or angiotensin receptor blocker, HbA1c ≤
64 mmol/mol, HbA1c ≤ 75 mmol/mol, asked about erectile dysfunction,
received advice about erectile dysfunction) are provided in Appendix B
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Table 1 Unadjusted and adjusted odds ratios (cancer compared with control) of meeting quality measures
Quality measure Cohort
Combined Breast cancer Colorectal cancer Prostate cancer
Unadjusteda Adjustedb Unadjusted Adjusted Unadjusted Adjusted Unadjusted Adjusted
Blood pressure ≤ 150/90 mmHg
Odds ratioc 1.02 1.05 0.96 1.00 0.96 0.96 1.14 1.16*
95% CI (0.93–1.13) (0.96–1.16) (0.81–1.14) (0.85–1.18) (0.81–1.14) (0.81–1.13) (0.97–1.13) (1.00–1.35)
Blood pressure ≤ 140/80 mmHg
Odds ratio 1.02 1.04 1.00 1.06 1.00 0.99 1.04 1.06
95% CI (0.94–1.10) (0.97–1.12) (0.87–1.15) (0.93–1.20) (0.88–1.14) (0.87–1.11) (0.92–1.18) (0.95–1.19)
Total cholesterol ≤ 5 mmol/L
Odds ratio 0.81***† 0.82***† 0.95 1.03 0.85 0.80**† 0.66***† 0.66***†
95% CI (0.73–0.89) (0.75–0.90) (0.80–1.15) (0.88–1.21) (0.72–1.01) (0.68–0.93) (0.57–0.77) (0.57–0.76)
Albumin creatinine ratio test
Odds ratio 0.81***† 0.83***† 0.78**† 0.80** 0.81* 0.81* 0.84* 0.86
95% CI (0.73–0.89) (0.75–0.91) (0.65–0.92) (0.68–0.95 0.67–0.97) (0.68–0.97) (0.72–0.99) (0.73–1.01)
ACE-I or ARBd
Odds ratio 0.64 0.48 0.85 0.57↑ 0.81 0.76↑ 0.44 0.33↑
95% CI (0.30–1.35) (0.21–1.10) (0.13–5.75) (0.05–5.98) (0.26–2.60) (0.23–2.56) (0.14–1.43) (0.09–1.14)
HbA1c ≤ 59 mmol/mol
Odds ratio 0.80***† 0.77***† 0.74** 0.72***† 0.79* 0.80*↑ 0.86 0.79**†
95% CI (0.72–0.89) (0.70–0.85) (0.60–0.90) (0.61–0.85) (0.65–0.97) (0.68–0.95) (0.72–1.02) (0.68–0.92)
HbA1c ≤ 64 mmol/mol
Odds ratio 0.78***† 0.75***† 0.76**† 0.74***† 0.76** 0.77**† 0.80* 0.73**†
95% CI (0.70–0.87) (0.68–0.82) (0.62–0.93) (0.63–0.88) (0.63–0.93) (0.65–0.91) (0.67–0.95) (0.63–0.85)
HbA1c ≤ 75 mmol/mol
Odds ratio 0.81***† 0.80***† 0.86 0.86 0.74** 0.76** 0.83* 0.79**†
95% CI (0.73–0.91) (0.73–0.89) (0.70–1.05) (0.72–1.03) (0.60–0.90) (0.63–0.91) (0.70–1.00) (0.67–0.93)
Influenza immunization
Odds ratio 1.26* 1.31**†↑ 0.93 0.95↑ 0.98 0.96↑ 2.04***† 2.18***†
95% CI (1.03–1.53) (1.07–1.59) (0.66–1.31) (0.68–1.34) (0.69–1.39) (0.67–1.36) (1.46–2.86) (1.56–3.06)
Retinal screening
Odds ratio 0.96 0.99 1.01 1.03 1.00 1.03 0.89 0.91
95% CI (0.88–1.05) (0.91–1.08) (0.87–1.18) (0.88–1.19) (0.85–1.18) (0.88–1.20) (0.77–1.03) (0.79–1.05)
Foot exam
Odds ratio 0.79**† 0.94 0.75* 0.88 0.76* 0.92 0.93 1.03
95% CI (0.68–0.92) (0.85–1.04) (0.57–0.98) (0.74–1.04) (0.58–0.99) (0.78–1.09) (0.71–1.21) (0.87–1.21)
Dietary review
Odds ratio 0.85 1.01 0.77 0.89 0.87 1.02 0.98 1.08
95% CI (0.70–1.03) (0.87–1.16) (0.53–1.13) (0.66–1.21) (0.66–1.14) (0.80–1.28) (0.69–1.39) (0.83–1.41)
Asked about erectile dysfunction
Odds ratio 0.94 1.06 NA NA 0.86 1.00 1.02 1.08
95% CI (0.77–1.16) (0.89–1.26) NA NA (0.64–1.15) (0.75–1.32) (0.78–1.34) (0.86–1.35)
Advice about erectile dysfunction
Odds ratio 1.55* 1.60** NA NA 1.17 1.26 1.68** 1.71**†
95% CI (1.09–2.19) (1.18–2.18) NA NA (0.65–2.11) (0.71–2.26) (1.14–2.48) (1.21–2.41)
ACE-I angiotensin-converting enzyme inhibitor, ARB angiotensin receptor blocker, HbA1c glycosylated hemoglobin, NA not applicable
*p < 0.05, **p < 0.01, ***p < 0.001
†Remained statistically significant after Benjamini-Hochberg adjustment for multiple comparisons
↑Goodness of fit of the model was significantly improved by adding an interaction term for time versus cancer, and interaction term indicates effect of
cancer over time was to increase the adjusted odds of the outcome measure in the cancer group
a Themultilevel logistic regression models for the unadjusted odds ratios also included time (years) as a factor variable and a random effect for the patient
b The regression models for the adjusted odds ratios also included age, sex (combined cohorts, colorectal cancer), year of index date, smoking status,
drinking status, body mass index, Charlson Comorbidity Index, Index of Multiple Deprivation score, baseline blood pressure, baseline total cholesterol,
baseline HbA1c, history of one or more microvascular complications of diabetes, history of one or more macrovascular complications of diabetes, and
history of diabetes medications
c Odds ratios: cancer compared to control
d In patients diagnosed with nephropathy or microalbuminuria
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and follow-up could undermine improvements in survival
among cancer patients, due to advances in early detection,
treatment, and supportive care [3, 4]. Our results show that
cancer patients who survived at least 1 year after diagnosis
were up to 34% less likely to meet quality measures for testing
and control of total cholesterol and HbA1c during the first
5 years after diagnosis. These findings were consistent across
the three cancer cohorts (except cholesterol in breast cancer).
Also, they were robust to varying the length of the observation
period, and to changing the composition of the cohorts. There
was no evidence that cancer was associated with lower adjust-
ed odds of blood pressure control, or with receiving any of the
other services in the Diabetes Mellitus Indicator Set, except
perhaps for foot examination.
Prostate cancer was associated with statistically significant-
ly higher adjusted odds of receiving influenza immunization.
Prostate cancer also was associated with statistically signifi-
cantly higher adjusted odds of receiving advice for erectile
dysfunction. One possible explanation for these findings is
that follow-up of prostate cancer, with the aims of checking
how cancer has responded to treatment, and helping patients
manage any side effects of treatment, increases the frequency
of appointments at the patient’s GP surgery, which in turn
provides more opportunities for providing routine primary
care, such as influenza immunization, to these patients. In
particular, regular prostate specific antigen testing may be per-
formed in the primary care setting, with subsequent appoint-
ments to review the results. Also, since GPs will be aware that
erectile dysfunction is a side-effect of treatment for prostate
cancer, and patients are encouraged to discuss symptoms or
treatment side-effects during their follow-up visits, prostate
cancer patients are more likely to receive advice about erectile
dysfunction.
Compared to Khan et al. [15], who investigated the im-
pact of cancer on testing and disease control in long-term
UK cancer survivors beginning 5 years after cancer diagno-
sis, cancer had less adverse impact on the odds of monitor-
ing and testing in our study. Of note, we found no impact on
blood pressure monitoring within 5 years after cancer diag-
nosis. Whereas Khan and colleagues found breast and pros-
tate cancer patients were less likely to receive monitoring
beginning 5 years after cancer. Also, in our study, cancer
was associated with poorer control of cholesterol and
HbA1c. Specifically, the adjusted odds of meeting the
HbA1c test threshold of ≤ 59 mmol/mol, which equates to
< 7.5% used by Khan and colleagues, were statistically sig-
nificantly lower in all three cancer cohorts versus only co-
lorectal cancer patients in the earlier study. Further, the ad-
justed odds of meeting the total cholesterol test threshold
were lower in colorectal and prostate cancer versus only
prostate cancer in the aforementioned study.
Our study has several strengths, which are in large part
attributable to the high quality of the database we used.
Since the study was based on CPRD we were able to control
for additional clinical factors typically not available in US
health insurance claim databases, which may have otherwise
confounded associations between cancer and the quality of
diabetes primary care outcome measures. These included
baseline BMI, smoking status, blood pressure, cholesterol,
and HbA1c. As most of the differences we observed between
cancer patients and controls occurred in the test result-based
quality measures, we believe that controlling for baseline test
values (at the same cut points as the quality measures) in the
multivariate analyses has removed an important source of po-
tential confounding. Second, the study design and analytical
approach allowed us to investigate within-person changes in
the adjusted odds of meeting the quality measures. Although
we cannot rule out the occurrence of other contemporaneous
(with the diagnosis of cancer) events, the fact that the results of
the seven-year analyses (including 2 years before the index
date) were virtually identical to those of the 5-year analyses
gives us greater confidence that cancer caused the differences
in quality measures we observed between cases and controls.
Third, since all of our quality measures were based on QOF
performance indicators, there are considerable incentives for
primary care practices to report the delivery of all services and
results pertaining to these indicators.
Our study also has several limitations. First, at the time it
was conducted we were unable to link the CPRD data to
information from the National Cancer Intelligence Network.
This would have given us details on cancer stage and initial
treatment. Although primary care data have a high sensitivity
and specificity for identifying cancer [32], registry data would
have allowed us to exclude cancer patients diagnosed with
metastatic disease. We considered using Read codes in the
primary care data files or International Classification of
Diseases, 10th Revision (ICD-10) codes in the Hospital
Episode Statistics (HES) inpatient data to stage patients.
However, we are not aware of any studies in the UK validating
the use of ICD-10 codes for this purpose, and since only two
thirds of patients in our study were linked to HES doing so
would have limited our sample sizes. Instead, we excluded
patients who died within the first year after their index date.
This approach could have resulted in including cancer patients
with relatively poor prognosis, for whom cancer care would
be prioritized over diabetes care; inclusion of such patients
could create a bias towards finding less receipt of recommend-
ed diabetes care among cancer patients. Second, we consid-
ered several approaches to missing data. We elected to con-
struct additional categories for missing values of predictor
variables because we believed in this instance Bmissingness^
might be informative, and possibly negatively correlated with
receiving diabetes primary care services. Third, we could not
account for diabetes services performed in secondary care
settings during cancer treatment that were not recorded in
the primary care data. Fourth, the measures of biological
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control, i.e., blood pressure, cholesterol, and HbA1c, that we
included in the study were binary variables based on threshold
values in the QOF diabetes indicator set [18]. These thresholds
have been established as indicators of high-quality diabetes
care, and they are part of the UK Bpay for performance^ sys-
tem for GP practices. However, an alternative (and perhaps
more sensitive) approach might have been to use the actual
laboratory values. Finally, our findings may not be generaliz-
able either to long-term survivors of breast, colorectal, and
prostate cancer in an era of full implementation of QOF, or
to other types of cancers and primary care services for other
comorbid conditions.
Conclusions
Overall, cancer appears to have had little adverse impact on
the delivery of high-quality diabetes primary care services
during the first 5 years after cancer diagnosis. However, can-
cer patients were less likely to achieve target thresholds for
cholesterol and HbA1c. Potential reasons, including the ef-
fects of cancer treatment and changes in patient health behav-
iors in response to cancer diagnosis, should be further inves-
tigated. Options to improve achievement of target thresholds
could include the development of specific indicators and in-
centives to promote greater coordination of care between on-
cologists and general practitioners, especially to identify and
address instances where cancer treatment may cause blood
sugar and/or cholesterol levels to rise, and the expansion of
diabetes programs that are tailored specifically to cancer
patients.
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